Clinical and therapeutic implications of follistatin in solid tumours
Open accessAbstract
Follistatin (FST), as a single-chain glycosylated protein, has two major isoforms, FST288 and FST315. The FST315 isoform is the predominant form whilst the FST288 variant accounts for less than 5% of the encoded mRNA. FST is differentially expressed in human tissues and aberrant expression has been observed in a variety of solid tumours, including gonadal, gastric and lung cancer, hepatocellular carcinoma, basal cell carcinoma and melanoma. Based on the current evidence, FST is an antagonist of transforming growth factor beta family members, such as activin and bone morphogenetic proteins (BMPs). FST plays a role in tumourigenesis, metastasis and angiogenesis of solid tumours through its interaction with activin and BMPs, thus resulting in pathophysiological function. In terms of diagnosis, prognosis and therapy, FST has shown strong promise. Through a better understanding of its biological functions, potential clinical applications may yet emerge.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
FST acts as a multi-faceted hepatokine involved in reproduction, muscle growth, cancer development, and metabolism.
“FST acts as a multi-faceted hepatokine that is involved in reproduction [181], muscle growth [182], cancer development [183], and metabolism [184].”
From Hepatokines and metabolism: Deciphering communication from the liver (2021) · cites this paper as [183]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 120 · Cited by 47
- Authors
- SHI, L., RESAUL, J., OWEN, S., YE, L., & JIANG, W. G.
- Affiliations
- Yuhuangding Hospital (CN)
- Cardiff University (GB)
- Venue
- Cancer Genomics & Proteomics
- Published
- 2016-10-26
- Volume
- 13
- Issue
- 6
- Pages
- 425-436
- ISSN
- 1109-6535 (ISSN-L)
- 1790-6245
- PMC
- PMC5219916
- OpenAlex
- W2546219240
- Cited by
- 47
- References
- 120
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 9 · 2023: 5 · 2022: 6 · 2021: 5 · 2020: 4 · 2019: 4 · 2018: 4 · 2017: 4
- FWCI
- 0.36
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Cancer Genomics & Proteomics (publishedVersion)
- PubMed Central (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed (publishedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
- Funders
- Cancer Research Wales
- Cardiff University
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Keywords
- follistatin, solid tumors, activin, bone morphogenetic proteins, tumourigenesis, metastasis, angiogenesis, cancer diagnosis, cancer prognosis, cancer therapy, melanoma, lung cancer, hepatocellular carcinoma, basal cell carcinoma, gastric cancer
- MeSH terms
- Humans, Neoplasms, RNA, Messenger, Gene Expression Regulation, Neoplastic, Transforming Growth Factor beta, Bone Morphogenetic Proteins, Protein Isoforms, Follistatin, Carcinogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
